Myrtelle Inc.
Industry
- Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
Latest on Myrtelle Inc.
The US Food & Drug Administration’s inaugural class of applications for its START rare disease pilot program includes three early-stage gene therapy programs intended to treat pediatric diseases, incl
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Taps Anima’s mRNA Platform, Immu
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Innoviva Acquisition Of Entasis Leaves
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Immatics Gets $150m Up Front For Rights